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We analyzed the structure of antigen receptors of a comprehensive panel of mature B non-
Hodgkin’s lymphomas (B-NHLs) by comparing, at the amino acid level, their immunoglobulin 
(Ig)V
 
H
 
-CDR3s with CDR3 sequences present in GenBank. Follicular lymphomas, diffuse large 
B cell lymphomas, Burkitt’s lymphomas, and myelomas expressed a CDR3 repertoire 
comparable to that of normal B cells. Mantle cell lymphomas and B cell chronic lymphocytic 
leukemias (B-CLLs) expressed clearly restricted albeit different CDR3 repertoires. Lymphomas 
of mucosa-associated lymphoid tissues (MALTs) were unique as 8 out of 45 (18%) of 
gastric- and 13 out of 32 (41%) of salivary gland-MALT lymphomas expressed B cell 
antigen receptors with strong CDR3 homology to rheumatoid factors (RFs). Of note, 
the RF-CDR3 homology without exception included N-region–encoded residues in the 
hypermutated 
 
IgV
 
H
 
 genes, indicating that they were stringently selected for reactivity with 
auto-IgG. By in vitro binding studies with 10 MALT lymphoma–derived antibodies, we 
showed that seven of these cases, of which four with RF-CDR3 homology, indeed possessed 
strong RF reactivity. Of one MALT lymphoma, functional proof for selection of subclones 
with high RF affinity was obtained. Interestingly, RF-CDR3 homology and t(11;18) appeared 
to be mutually exclusive features and RF-CDR3 homology was not encountered in any of the 
19 pulmonary MALT lymphomas studied.
 
B cell non-Hodgkin’s lymphomas (B-NHLs)
comprise 
 
 
 
85% of malignant lymphomas
worldwide. They are in majority of germinal
center (GC) or post-GC phenotype and often
harbor chromosomal translocations typically
involving immunoglobulin (Ig) loci (1). In
spite of their genetic defects, most B-NHLs do
not replicate spontaneously in vitro, indicating
that they still depend on environmental stimuli
for their growth. To date, these external fac-
tors are ill defined. Evidence exists that B cell
antigen receptor (BCR) ligands have, as in
normal B cell development, a pivotal role in
the pathogenesis of at least some B-NHLs. For
example, the architecture and cellular compo-
sition of follicular lymphomas (FLs) is highly
reminiscent of normal GCs. Furthermore,
extranodal marginal zone B cell lymphomas
(MZBCLs) of mucosa-associated lymphoid tissue
(MALT) arise at sites of antigenic stimulation due
to organ-specific autoimmunity; e.g., Sjögren’s
sialadenitis (2) and Hashimoto’s thyroiditis (3),
or infection like 
 
Helicobacter pylori
 
 gastritis (4,
5) and 
 
Borrelia burgdorferi
 
 dermatitis (6, 7), re-
spectively. Similarly, a role of hepatitis C virus
(HCV) infection has been inferred in the de-
velopment of malignant B cell proliferation,
including splenic MZBCL and MALT lym-
phoma (8, 9). Most recently, it has been
claimed that ocular adnexal MALT lymphoma
and immunoproliferative small intestinal disease
(also known as 
 
 
 
-heavy chain disease) are asso-
ciated with 
 
Chlamydia psittaci
 
 and 
 
Campylobacter
jejuni
 
 infections, respectively (10, 11). The low
tendency of MALT lymphomas to spread be-
yond the environment in which they evolve
may be related to the expression of certain
homing and chemokine receptors, such as
 
 
 
4
 
 
 
7 and CXCR3 (12, 13). In addition, it has
been proposed that even during the tumor
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RHEUMATOID FACTOR PRODUCTION BY MALT LYMPHOMAS | Bende et al.
 
1230
 
stage, antigen (Ag) plays a growth-sustaining role. This no-
tion is strongly supported by the observation that a propor-
tion of low grade gastric MALT lymphomas (14, 15) and
skin MZBCLs (7) are curable by bacterial eradication alone,
while interferon 
 
 
 
-2b treatment can cause regression of
HCV-associated MZBCLs (16, 17).
Analysis of the Ig variable (
 
IgV
 
) genes supported the con-
cept of Ag-driven lymphomagenesis in FL and MALT lym-
phoma. The IgV heavy (
 
IgV
 
H
 
) and IgV light (
 
IgV
 
L
 
) chain
genes of these malignancies are heavily mutated, compatible
with a GC or post-GC derivation (18–22). The mutation
patterns unequivocally indicate that Ag-based selection oc-
curs at some stage of their development; despite high muta-
tion loads, the overall structure of the Ig is generally being
preserved in these lymphomas often during years of disease.
Apparently, selective forces prevent the outgrowth of BCR
 
 
 
lymphoma mutants.
Although many studies on FL and MALT lymphomas al-
lude to a role for Ag in the pathogenesis of these lympho-
mas, only sporadic data exist on the exact ligands that these
B cell neoplasms might recognize. Although the obvious
candidate ligand for gastric MALT lymphoma was 
 
H. pylori,
 
in vitro cultures revealed that the tumor B cells were not di-
rectly stimulated by 
 
H. pylori
 
, but indirectly by CD40/
CD40L-mediated help of intratumoral, 
 
H. pylori
 
–specific T
cells (23). Hussell et al. (24) and Greiner et al. (25) observed
reactivity of MALT lymphoma–derived Abs with follicular
DCs (FDCs), various epithelia, or postcapillary venules of
Peyer’s patches, but no specific Ags were molecularly de-
fined. It is well documented that a significant proportion of
B cell chronic lymphocytic leukemias (B-CLLs) express Ig
(poly) reactive with a diversity of autoantigens (26–31). In
contrast, with other B-NHL entities, autoreactivity has only
sporadically been reported (32–34). Finally, viral antigens of
HTLV-I and HCV have been implicated as BCR ligands of
individual cases of B-CLL (35) and diffuse large B cell lym-
phoma (DLBCL; reference 36), respectively.
To address the issue of antigen-receptor specificity of
B-NHL, we performed a systematic analysis of the antigen
binding sites of 132 extranodal MZBCL (24 from our labo-
ratory and 108 from literature) and, for comparison, from a
comprehensive panel of 478 other B-NHL. We provide ev-
 
Table I.
 
Clinical presentation, immunohistochemistry, and genetics of 24 MALT lymphomas
 
Immunohistochemistry PCR
Patient Sex Age Location Clinical presentation Ig isotype Light chain CXCR3
 
 
 
4
 
 
 
7 t(11;18)
 
M4 f 60 thyroid gland Hashimoto’s thyroiditis NC
 
      
 
M5 f 64 parotid gland Sjögren’s syndrome IgM
 
      
 
M6’95 f 55 stomach gastritis ND
 
      
 
M6’96 f 56 stomach gastritis IgM
 
    
 
ND
M8 m 44 parotid gland unknown IgM
 
      
 
M9 f 58 tonsil unknown IgM
 
      
 
M11 m 38 parotid gland unknown IgM
 
      
 
M13 m 63 ileum unknown NC NC
 
    
 
M14 f 70 parotid gland Sjögren’s syndrome IgA
 
      
 
M15 f 45 lacrymal gland Sjögren’s syndrome IgA
 
      
 
M19 f 74 lung unknown IgM
 
      
 
M20 m 39 lung unknown IgM/IgA
 
      
 
M21 f 64 parotid gland Sjögren’s syndrome IgM
 
      
 
M22
 
a
 
m 71 groin lymph node unknown IgA
 
      
 
M23 m 52 lung unknown IgG
 
      
 
M30 f 60 stomach gastritis NC
 
 
 
ND ND
 
 
 
M41 f 55 stomach gastritis ND ND ND ND
 
 
 
M45 m 81 stomach gastritis ND ND ND ND
 
 
 
M46 m 65 stomach gastritis ND ND ND ND
 
 
 
M55 m 41 lung unknown ND ND ND ND
 
 
 
M56 m 78 stomach gastritis IgM
 
      
 
M57 m 81 stomach gastritis IgM
 
      
 
M58 m 74 stomach gastritis IgM NC
 
    
 
M60 m 71 stomach gastritis IgM
 
      
 
M61 m 38 stomach gastritis IgM
 
      
 
a
 
Initially located in salivary gland.
NC, not clear. 
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idence that among the various B cell neoplasms, gastric- and
salivary gland-MALT lymphomas express a distinctive Ig
repertoire and frequently originate from precursor B cells
clonally selected for auto-IgG binding capacity. The fact that
B-NHL entities express qualitatively different Igs points to-
ward different roles of the BCRs in their pathogenesis.
 
RESULTS
IgV
 
H
 
 and IgV
 
L
 
 sequence analysis of MALT lymphomas
 
A panel of 24 MALT lymphomas was analyzed (Table I). All
lymphomas were CD20
 
 
 
 and virtually all expressed the
chemokine receptor CXCR3 and the mucosal homing inte-
grin 
 
 
 
4
 
 
 
7. The pulmonary lymphomas 
 
M19, M20,
 
 and 
 
M23
 
and the gastric lymphomas 
 
M56, M57, M58, M60,
 
 and 
 
M61
 
carried the t(11;18), involving the 
 
API2
 
 and 
 
MALT1
 
 genes
(Table I). Except for 
 
M60
 
, all 
 
IgV
 
H
 
 and 
 
IgV
 
  
 
genes analyzed
were somatically mutated with means of 21 (range 0–68) and
18 mutations (range 1–58) per IgV gene, respectively (Tables
II and III). Of 
 
M6,
 
 biopsies were available of two time points
spanning a 9 mo interval. At relapse (
 
M6
 
 
 
96
 
), 15 somatic mu-
tations were found in the expressed V3-7 
 
IgV
 
H
 
 gene while at
presentation (
 
M6
 
 
 
95
 
) an additional replacement mutation in
codon 13 had been present (Table II). Immunohistochemis-
try (Table I) and RT-PCR (Table II) indicated that the lung
lymphoma 
 
M20
 
 contained both IgM- and IgA-expressing tu-
mor cells. The IgM- and the IgA-related 
 
IgV
 
H
 
 sequences
were identical and contained 5 mutations (Table II). In 17 of
the 24 lymphomas (71%), the replacement versus silent (R/S)
mutation ratios in the framework regions (FRs) of the 
 
IgV
 
H
 
genes, were significantly 
 
 
 
1.5, implying that, in spite of the
high mutation frequencies, selective forces had preserved the
BCR in these lymphomas (unpublished data). Intraclonal
variation (ICV) was determined for 16 
 
IgV
 
H
 
 genes and for 8
 
IgV
 
 
 
 genes (18). In 10 out of the 16 (63%) MALT lympho-
 
Table II.
 
Immunoglobulin variable heavy chain genes of 24 MALT lymphomas
 
Patient
Ig isotype
(RT-PCR) VH family
Closest VH
germline gene No. of mutations (%) D gene JH gene Intraclonal variation
 
a
 
M4
 
 
 
VH3 V3-23 (DP47) 68 (23) NA JH4b 0.8 (5)
M5
 
 
 
VH3 V3-7 (DP54) 17 (5.8) D3-3 JH3b 0.8 (5)
M6’95
 
 
 
VH3 V3-7 (DP54) 16 (5.4) D3-22 JH3b ND
M6’96
 
 
 
VH3 V3-7 (DP54) 15 (5.1) D3-22 JH3b 1.0 (5)
M8
 
 
 
,δ
 
b
 
VH3 V3-30 (DP49) 26 (8.8) D5-24 JH5 ND
M9
 
 
 
,δ
 
b
 
VH1 V1-69 (DP10) 8 (2.7) NA JH4b ND
M11
 
 
 
VH1 V1-69 (DP10) 11 (3.7) D6-13 JH4b 3.0 (7)
M13
 
 
 
VH4 V4-31 (DP65) 14 (4.7) D5-24 JH4 1.8 (5)
M14
 
 
 
VH3 V3-23 (DP47) 43 (15.0) NA JH6 2.3 (6)
M15
 
 
 
VH1 V1-18 (DP14) 46 (16.0) NA JH4b
 
 
 
0.4 (5)
M19
 
 
 
,δ
 
b
 
VH3 V3-53 29 (10.0) NA JH4b ND
M20
 
 
 
,
 
 
 
VH4 V4-30.4 (DP78) 5 (1.7) NA JH3b ND
M21
 
 
 
,δ
 
b
 
VH3 V3-23 (DP47) 23 (7.8) D2-2 JH4b 0.7 (11)
M22
 
 
 
VH1 V1-69 (DP88) 14 (4.8) D4-17 JH4b
 
 
 
0.4 (15)
M23
 
 
 
VH1 V1-69 (DP88) 7 (2.4) NA JH4b
 
 
 
0.4 (7)
M30
 
 
 
VH2 V2-5 (VII-5) 33 (11.1) NA JH1 0.7 (7)
M41 ND VH1 V1-69 (DP10) 19 (6.5) D3-22 JH4b  0.4 (7)c
M45 ND VH1 V1-3 (DP25) 22 (7.5) D3-10 JH4b ND
M46 ND VH3 V3-30/30.5 (DP49) 12 (4.1) D5-12 JH6b ND
M55 ND VH3 V3-7 (DP54) 24 (8.1) D3-22 JH4b ND
M56   VH1 V1-69 (DP10) 7 (2.4) D1-14 JH4b  0.4 (11)
M57   VH1 V1-18 (DP14) 14 (4.8) NA JH6b 1.9 (9)
M58   VH3 V3-53 23 (7.9) D3-22 JH4b ND
M60   VH1 V1-69 (DP10) 0 (0.0) D2-15 JH5b  0.4 (9)
M61   VH1 V1-18 (DP14) 19d (6.5) D2-15 JH4b 0.8 (4)
aThe intraclonal variation is indicated as the mean number of nucleotide differences observed per clone, as compared with the consensus sequence. Numbers in parentheses in-
dicate the number of clones that were sequenced.
bIgD was not detected immunohistochemically.
cM41 contained distinct subclones (Fig. 1).
dM61 had a deletion of the three nucleotides of codon 29.
NA, the germline D gene could not definitely be assigned.RHEUMATOID FACTOR PRODUCTION BY MALT LYMPHOMAS | Bende et al. 1232
III). In M15, lacking ICV in the IgVH gene, an exceptionally
high degree of ICV was observed in its IgV  gene (Tables II
and III). Interestingly, M41 appeared a somatically diversified,
V1-69/D3-22/JH4b-expressing lymphoma, harboring dis-
tinct subclones (M41-A, B, C, and D) with 19, 19, 20, and 2
mutations, respectively (Fig. 1).
IgVH-CDR3 amino acid sequences of MALT lymphomas 
and splenic MZBCL
We compared the IgVH-CDR3 amino acid (aa) sequences of
our panel of MALT lymphomas to IgVH-CDR3 aa sequences
present on GenBank using the NCBI Protein-BLAST pro-
gram with the option “search for short nearly exact matches”
(BLASTP 2.2.6; reference 37). CDR3 regions consisting of at
least 7 aa (all except M20) were analyzed (Table IV). A CDR3
sequence was considered to be homologous to previously re-
ported CDR3 sequences on GenBank (a) if sharing at least
75% aa sequence homology and (b) a length difference be-
tween the CDR3 sequences not exceeding 3 aa (maximum
gap of 3 aa). Applying these homology criteria, we found that
the CDR3 of 4 MALT lymphomas (M23, M46, M56, and
M60) displayed homology to different B cell clones analyzed
previously in repertoire studies. Interestingly, 4 cases (M5,
Table III. Immunoglobulin variable light chain   genes of 
the MALT lymphomas
Patient
V 
family
Closest V 
germline gene
No. of
mutations (%)
J 
gene
Intraclonal
variationa
M4 V 1 L9 (Ve ) 58 (20.0) J 4 0.5 (4)
M5 V 3 L2 (kv328, DPK21) 9 (3.2) J 1 1.0 (5)
M6’96 V 3 L2 (kv328, DPK21) 5 (1.8) J 1 0.4 (5)
M8 V 1 O12/O2 (DPK9) 27 (9.5) J 4N D
M9 V 3 A27 (kv325, DPK22) 2 (0.69) J 1N D
M11 V 3 A27 (kv325, DPK22) 1 (0.35) J 1 1.5 (6)
M14 V 2 A19/A3 (DPK15) 51 (17.0) J 4 1.2 (6)
M15 V 4 B3 (DPK24) 17 (5.6) J 4 9.3 (6)
M21 V 3 A27 (kv325, DPK22) 13 (4.5) J 1 0.5 (4)
M22 V 3 A27 (kv325, DPK22) 6 (2.1) J 2N D
M23 V 1 O12/O2 (DPK9) 6 (2.1) J 1 0.8 (8)
aThe intraclonal variation is indicated as the mean number of nucleotide differences 
observed per clone, as compared to the consensus sequence. Numbers in parenthe-
ses indicate the number of clones that were sequenced.
Figure 1. Schematic representation of the IgVH clones identified in 
M41. The lollipop-shaped symbols indicate nucleotide differences as com-
pared with the V1-69 (DP10) germline IgVH gene. Except for the CDR3 region, 
replacement and silent mutations are indicated with closed and open circles, 
respectively, with codon numbering according to V-base indicated under-
neath. 2 , two mutations in the indicated codon. The mutations in codons 
76 and 82a are different between M41-A/B and M41-C, respectively. In the 
CDR3 and in codon 106, interclonal differences are indicated by different 
filling patterns of the circles. In the CDR3, the deduced aa sequence is 
depicted in the one-letter code underneath. The CDR3 of M41-A/D, M41-B 
and M41-C displayed, respectively, 73, 82, and 91% homology to the CDR3 
of RF-WOL. M41-D has only two mutations, shared with M41-A, B, and C.
mas, significant ICV was found in IgVH (Table II). Except for
M6, all lymphomas with ICV in IgVH genes also displayed
ICV in the IgV  genes, generally of a lower degree (TableJEM VOL. 201, April 18, 2005 1233
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M6, M11, and M41) showed strong homology with CDR3
sequences of other MALT lymphomas, as well as with CDR3
sequences of rheumatoid factors (RF). Salivary gland lym-
phoma M5 and gastric lymphoma M6, both expressing a V3-
7/JH3 rearrangement, were homologous to a plethora of
IgVH-CDR3 aa sequences originating from salivary gland
MALT lymphomas, gastric MALT lymphomas, HCV-associ-
ated lymphomas, B cell clones derived of benign myoepithe-
lial sialadenitis, one DLBCL and two genuine V3-7–encoded
RFs (Table S1, available at http://www.jem.org/cgi/content/
full/jem.20050068/DC1). Salivary gland lymphoma M11,
which expressed a V1-69/JH4 rearrangement, was homolo-
gous to five normal B cell clones, one salivary gland MALT
lymphoma Isolate-4 (38), and three V1-69-encoded RFs (Ta-
ble S1). Interestingly, Isolate-4 is one of the five cases described
by Miklos et al. (38) having distinct CDR3 characteristics, in-
dicating that M11 belongs to this group which is characterized
by distinct aa motifs (ERG and NP) at the VH-DH- and the
DH-JH-junctions, respectively. Gastric MALT lymphoma
M41, which also expressed V1-69/JH4, was homologous to
HCV-associated lymphomas of different histological subtypes,
one splenic MZBCL, one salivary gland MALT lymphoma,
one gastric MALT lymphoma and finally to one RF termed
RF-WOL (reference 39 and Table S1).
We then, additionally, examined CDR3 of 35 gastric-,
26 salivary gland- and 15 pulmonary-MALT lymphomas as
well as 32 splenic MZBCL from literature and/or GenBank
(Table V). This revealed that overall 8 out of 45 (18%) gas-
tric- and 13 out of 32 (41%) salivary gland-MALT lympho-
mas expressed IgVH-CDR3 with RF homology. Three ma-
jor RF homology groups could be distinguished, i.e., nine
encoded by V1-69/JH4 (V1-69-RF), eight by V3-7/JH3
(V3-7-RF) and three by V1-69/JH4 (RF-WOL) rearrange-
ments, respectively (Table V). Intriguingly, in all cases ho-
mology areas included aa encoded by the nontemplated nu-
cleotide (N) regions (Fig. 2). In addition, gastric MALT
lymphoma  ML15 (40) was homologous to another RF
termed RF-C93 (41). Noteworthy, none of the 19 pulmo-
nary MALT lymphomas expressed RF-homologous CDR3
whereas among the splenic MZBCLs, only one case ex-
pressed a CDR3 homologous to RF-WOL (Table V).
Currently, 10 genuine V1-69/JH4-encoded RFs, iso-
lated from rheumatoid arthritis patients or from healthy do-
nors immunized with mismatched red blood cells (HID),
Table IV. Amino acid sequences of the variable heavy chain CDR3 of the 24 MALT lymphomas
Patient VH-D-JH rearrangement CDR3 amino acid sequencea CDR3 length
aa
M4 V3-23 (DP47)/JH4b CTK AHVPYFDGLSPSNV WGQG 14
M5 V3-7 (DP54)/D3-3/JH3b CAR GD FWSGDY ID AFDI WGQG 14
M6 V3-7 (DP54)/D3-22/JH3b CAR GD YFDSSGSF ID AFDI WGQG 16
M8 V3-30 (DP49)/D5-24/JH5 CAK DGSEFRLIY WFDS WGRG 13
M9 V1-69 (DP10)/JH4b CAR DWAHQGETRSNFLYY WGQG 15
M11 V1-69 (DP10)/D6-13/JH4b CAR E GIAAA VNP FDY WGQG 12
M13 V4-31 (DP65)/D5-24/JH4 CAG D RGGYN LL DC WGHG 10
M14 V3-23 (DP47)/JH6 CAK QMGLAGTQR FYGLDV WGKG 15
M15 V1-18 (DP14)/JH4b CAR ATLDLDGYM DF WGQG 11
M19 V3-53/JH4b CAT PISGTYHLY Y WGQG 10
M20 V4-30.4 (DP78)/JH3b CAR DQ AFDI WGQG 6
M21 V3-23 (DP47)/D2-2/JH4b CAK DLFFV GYCTTTGC NT FDY WGQG 18
M22 V1-69 (DP88)/D4-17/JH4b CAR GSN DYGDN VPVQPH Y WGQG 15
M23 V1-69 (DP88)/JH4b CAR VSGNSH FDY WGQG 9
M30 V2-5 (VII-5)/JH1 CAQ RGGFYDSSLGFYIAPFP H WGQG 18
M41-A V1-69 (DP10)/D3-22/JH4b CAR GP DTGGYYY F Y WGQG 11
M41-B V1-69 (DP10)/D3-22/JH4b CAR GP DTGDYYY F Y GGQG 11
M41-C V1-69 (DP10)/D3-22/JH4b CAR GP DSSNYYY F Y WGQG 11
M45 V1-3 (DP25)/D3-10/JH4b CAR GTKIRGIVKPFP DY WGQG 14
M46 V3-30/30.5 (DP49)/D5-12/JH6b CAK DSGYVNFYYT MDV WGQG 13
M55 V3-7 (DP54)/D3-22/JH4b CAK WDYENSAYFLH Y WGQE 12
M56 V1-69 (DP10)/D1-14/JH4b CAR DT GN H YFDY WGQG 9
M57 V1-18 (DP14)/JH6b CAT PPPRAGDGP YYYYGMDV WGQG 17
M58 V3-53/D3-22/JH4b CAR HSYDNNAY DF WGQG 10
M60 V1-69 (DP10)/D2-15/JH5b CAR DPVD CSGGSCY LS WFDP WGQG 17
M61 V1-18 (DP14)/D2-15/JH4b CAR D YCSGGICY GG DY WGQG 13
aThe FR3 and FR4 are indicated in italics. The assignable nontemplated region-encoded amino acids are underlined.RHEUMATOID FACTOR PRODUCTION BY MALT LYMPHOMAS | Bende et al. 1234
have been described (42). V1-69/JH4 RFs typically contain
a 12–14 aa CDR3 and are combined with an A27(kv325)-
encoded IgV  chain. Among the V1-69-RF-homologous
MALT lymphomas, only of salivary gland lymphoma M11
the IgV  is known, which indeed proved to be the canoni-
cal A27(kv325) IgV  (Table III and Table S2, available at
http://www.jem.org/cgi/content/full/jem.20050068/DC1).
WOL-RF is also V1-69/JH4-encoded, but with a distinct 13
aa CDR3, again in combination with an A27(kv325)-encoded
IgV  chain. Five V3-7 RFs have been described, isolated
from HIDs and an RA patient (42).V3-7-RFs are encoded
by V3-7/D3-22/JH3 rearrangements, typically possessing a
16–17 aa CDR3 with the D3-22 in reading-frame 2, and in
combination with an L2 (kv328)/J 1-encoded IgV  chain.
The V3-7/JH3-expressing salivary gland lymphomas M5
and SH (43) and gastric MALT lymphoma M6 indeed all co-
expressed the canonical L2 (kv328)/J 1-encoded IgV 
chain (Table III and Table S2).
IgVH-CDR3 amino acid sequences of other mature B-non 
Hodgkin’s lymphomas
For comparison, IgVH-CDR3 analyses were extended to a
comprehensive panel of other mature B-NHLs available
from literature and/or on GenBank. For most B-NHL enti-
ties, the average CDR3 aa length was comparable to that of
mature naive B cells being 13,5 aa (44). Only splenic MZB-
CLs and the IgVH-unmutated B-CLLs expressed CDR3 of
higher mean lengths (Table V). Of 48 FLs, 20 DLBCLs, 48
Burkitt lymphomas (BL) and 31 myelomas, only 16 cases
(11%) displayed CDR3 aa homology with other CDR3 se-
quences present in GenBank. Thirteen of the 16 cases re-
sembled those of normal B cells analyzed in repertoire stud-
ies (45–47). As mentioned above, one DLBCL EJ (48)
showed homology to several gastric- and salivary gland-
MALT lymphomas as well as to V3-7-RFs (Table V).
Analyses of 23 mantle cell lymphomas (MCL), deposited
on GenBank, revealed that their CDR3 displayed a high fre-
quency of homology (10 out of 23, 44%), mostly (7 cases)
with CDR3 regions of unmutated normal B cells.
We analyzed a panel of 308 B-CLLs, 165 (54%) and 143
(46%) of the IgV-unmutated and the IgV-mutated subsets, re-
spectively (Table V). Overall, the CDR3s of 97 out of the 308
B-CLLs (31%) displayed CDR3 homology, 59 of which
(19%) with CDR3s of B-CLLs (inter B-CLL homology). Of
the group of 97 B-CLLs with any homology, 75% belonged
to the IgV-unmutated subset. This relative overrepresentation
was even more outspoken among the group with inter-
B-CLL homology in which 50 out of the 59 cases (85%) were
unmutated. In fact, applying our criteria for homology, we
distinguished eight CDR3-homology groups within 37 of
these 59 B-CLLs, each of which with at least three representa-
tives (Table VI). Very recently, B-CLL homology groups, ex-
cept for our group 8, have been identified by other investiga-
tors as well based on distinct homology criteria (references
49–52 and supplemental legend to Table VI, available at http:
//www.jem.org/cgi/content/full/jem.20050068/DC1).
Table V. Comparison of IgVH-CDR3 amino acid sequences of a panel of mature B-NHL with IgVH-CDR3 amino acid 
sequences from GenBank
No. of cases with CDR3 homology
Type of lymphoma Mean CDR3 length N Overalla RFb V1-69 RFc V3-7 RFc WOL-RFc
aa (%) (%)
Gastric MALT 13.6 45 16 (36) 8 (18) 1 4 2
Salivary gland MALT 14.5 32 15 (47) 13 (41) 8 4 1
Pulmonary MALT 12.7 19 2 (11) 0 (0) 0 0 0
Other MALT NI 4 0 (0) 0 (0) 0 0 0
Splenic MZBCL 16.3 32 8 (25) 1 (3) 0 0 1
MCL 13.3 23 10 (44) 0 (0) 0 0 0
B-CLL IgVH unmutated 17.4 165 73 (44) 2 (1) 0 0 0
B-CLL IgVH mutated 13.7 143 24 (17) 0 (0) 0 0 0
FL 12.1 48 4 (8) 0 (0) 0 0 0
DLBCL 12.2 20 2 (10) 1 (5) 0 1 0
BL 12.6 48 5 (10) 0 (0) 0 0 0
Myeloma 13.0 31 5 (16) 0 (0) 0 0 0
The lymphomas used for the homology analyses are listed in the supplemental legend to this table (available at http://www.jem.org/cgi/content/full/jem.20050068/DC1).
aIndicates the number of lymphomas that show at least 75% homology, according to the criteria described, to at least one IgVH-CDR3 sequence present in GenBank.
bIndicates the number of lymphomas that show homology to known rheumatoid factor (RF) IgVH-CDR3 sequences.
cIndicates the number of lymphomas with homology to canonical V1-69-, V3-7-encoded RFs and to WOL-RF. All the B-NHL that expressed RF homologous CDR3 regions are as 
follows: Gastric MALT lymphomas: ML13 homology to V1-69-RF; ML25, ML27, ML39a, and M6 homology to V3-7-RF; ML16 and M41 homology to WOL-RF; and ML15 homol-
ogy to C93-RF. Salivary gland MALT lymphomas: Isolate 1–5, PO-1, BA-2.2, and M11 homology to V1-69-RF; G552, SH, Isolate 10, and M5 homology to V3-7-RF; and JA-1 ho-
mology to WOL-RF. Splenic MZBCL: Isolate 1 homology to WOL-RF. B-CLL unmutated: CLL011 homology to TB-3-D13-RF and ID-74 homology to SJ2-RF. DLBCL: EJ homology 
to V3-7-RF.
NI, not informative.JEM VOL. 201, April 18, 2005 1235
ARTICLE
A significant fraction of B-CLLs derives from poly (auto)
reactive B cells (26–30). In vitro RF reactivity has been
proven for one representative of homology group 1 (POR)
and one of group 2 (AIG) (30). Two B-CLLs, CLL-011 (53)
and ID-74 (54) (CLL-011 belonging to homology group 1),
showed CDR3 homology to two different, IgVH-unmu-
tated, RFs termed TB-3-D13 (55) and RF-SJ2 (56), respec-
tively (Table V). Poly-reactivity toward different auto-anti-
gens, including IgG, has been demonstrated for homology
group 4 member SMI (29). In addition, group 4 members
share CDR3 homology with an anti-cardiolipine Ab
(AF460965). It is noted that the B-CLLs that displayed in
vitro RF reactivity (POR, AIG, and SMI) as well as the two
B-CLLs (CLL-011 and ID-74) that displayed CDR3 ho-
mology to two unmutated RFs, all belong to the IgV-unmu-
tated B-CLL subset. This clearly contrasts with the MALT
lymphomas with V1-69-RF, V3-7-RF or WOL-RF ho-
mology as these RFs as well as the MALT lymphoma Igs are
encoded by heavily mutated IgVH genes. Finally, none of the
308 B-CLLs showed CDR3 homology to V1-69-, V3-7-,
or WOL-RFs.
RF activity of recombinant lymphoma-derived 
IgM antibodies
To prove that MALT lymphomas with RF-CDR3 homol-
ogy possess IgG-binding activity, lymphoma-idiotype-
derived Abs (LIDA) of IgM class were generated of M5, M6,
M11, and M41-A, C, and D. Since, due to shortage of
DNA, we could not resolve the IgV  of M41 we combined
each of the IgVH variants of the M41-A, C, and D subclones
with the RF-canonical IgV  chain of M22. Recombinant
IgM LIDAs were also produced of 6 MALT lymphomas
(M8, M9, M14, M21, M22, and M23), which are all devoid
of RF-CDR3 homology. As additional controls, IgM LIDAs
were generated of four follicular lymphomas (FL1, FL6 94,
FL8 92, and FL13), one B-CLL, B-CLL26, and two anti-
Rhesus(D) Ab producing B cell lines (8D8 and LOS3; refer-
ence 57). The IgVH and IgV  sequences of these FLs and
Figure 2. IgVH-CDR3 amino acid sequences of selected cases of MALT 
lymphoma with homology to IgVH-CDR3 of rheumatoid factors. MALT 
lymphomas M5/M6, M11, and M41 share homology with V3-7-RF, V1-69-RF, 
and WOL-RF, respectively. In addition, RF CDR3 homology of three MALT 
lymphoma cases from literature (ML27, Iso-3, and ML16) with V3-7-RF, 
V1-69-RF, and WOL-RF, respectively, is depicted. The amino acid sequences 
are depicted by the single letter code. FR3 and FR4, framework region 3 and 4; 
N, amino acids encoded by the nontemplated nucleotides; D, gene segment; 
JH, gene segment; |, identical amino acids;  , similar amino acids; x, non-
matching amino acids; CDR3 length, length of the CDR3 region; Hom, per-
centage of homologous amino acids; Id, percentage of identical amino acids; 
Gap, length difference in amino acids of the compared IgVH-CDR3 regions.RHEUMATOID FACTOR PRODUCTION BY MALT LYMPHOMAS | Bende et al. 1236
B-CLL have been previously reported by us (18, 58, 59). The
lymphomas originally expressed IgM, with exception of
M14, M22 (both IgA ), and M23 FL6 94, FL8 92 (both
IgG ) (Tables I and II). RF-ELISA studies pointed out that
the LIDA of M5, M6, and M11 were indeed strongly reac-
tive with human IgG (Fig. 3). The LIDA of M9 and M22,
both with a IgVH-CDR3 region not completely fulfilling
our homology criteria but both with the RF-canonical V1-
69/JH4-A27(kv325) combination of IgVH and IgV  chains,
also displayed strong RF activity (Tables II–IV and Fig. 3).
Of note, also sera of patient M22, which contained high
concentrations (22 mg/ml and 6.5 mg/ml) of lymphoma-
related IgA paraprotein, displayed strong IgA-RF activity in
ELISA (Fig. 3). This thus independently confirmed our find-
ing with the M22-LIDA and underscored the validity of our
approach of recombinant lymphoma Ab production in the
eukaryotic expression system used. Moreover, the LIDA of
M21, not even harboring an RF-canonical IgVH rearrange-
ment but with an A27(kv325)-encoded IgV  chain, also
possessed strong RF activity. In contrast, none of the LIDAs
of MALT lymphomas M8, M14, M23, the four FLs, the
B-CLL nor the anti-Rhesus(D) Abs, all, except M23, lack-
ing canonical IgVH RF rearrangements, bound to IgG (Fig.
3). Finally, LIDA M41-A/M22 (the dominant subclone with
19 mutations) and M41-C/M22 with 20 mutations bound
Table VI. B-CLL IgVH-CDR3 amino acid sequence homology groups
Group Characteristic VH-D-JH
Mutation
status
CDR3
length
No. of
cases
aa
1 (VH1, VH5, VH7)/D6-19 (frame 3)/JH4 unmutated 11–12 9
2 (V1-69/V4-34)/D2-2 (frame 3)/JH6 unmutated 18–20 6
3 V4-34/D5-5 (frame 1)/JH6 mutated 18 3
4 V1-69/D3-16 (frame 3)/JH3 unmutated 19 3
5 (V1-2/V1-3)/D1-26 (frame 3)/JH6 unmutated 15 3
6 V4-39/D6-13 (frame 1)/JH5 unmutated 16-17 5
7 V1-69/D3-10 (frame 3)/JH6 unmutated 18 5
8 (V1-2/V1-46)/D3-22 (frame 2)/JH4 unmutated 17 3
The B-CLL cases of the eight IgVH-CDR3 homology groups and the resemblance of 
homology groups 1–7 to earlier described B-CLL homology groups are in the 
supplemental legend of this table.
Figure 3. RF activity of lymphoma-idiotype-derived antibodies. 
(a) Titration of IgM LIDAs M5, M6, M9, M11, M21, M22, M41-A, M41-B, 
FL6’94, B-CLL26, 8D8, and RF control serum in the IgM-RF ELISA. The LIDAs 
M8, M14, M23, M41-D, FL1, FL8’92, FL13, and LOS3 did not react with human 
IgG and showed a similar binding curve as that of FL6’94. (b) Binding 
activity of IgM LIDAs, RF control serum, and anti-Rh(D) control IgM Abs 
(LOS3 and 8D8) in the IgM-RF ELISA. All samples were tested at a stratified 
concentration of 500 ng/ml IgM. The ABS 450 nm is plotted without sub-
traction of the background (BG) ABS 450 nm. (c) IgA-RF ELISA of two serum 
samples of M22 and as controls an IgA anti-Rh(D) Ab (VT-7G3), an IgA-RF-
containing serum, the RF control serum that was also used in the IgM-RF 
ELISA, and two negative-control serum samples, respectively. All samples 
were tested at a stratified concentration of 20  g/ml IgA. The net ABS 450 
nm is plotted with subtraction of the background ABS 450 nm.JEM VOL. 201, April 18, 2005 1237
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IgG in ELISA whereas the LIDA of M41-D/M22 (a sub-
clone with only two mutations) did not (Figs. 1–3).
We next tested the binding capacities of the RF  LIDAs
of M5, M6, M9, and M11 with recombinant IgG1 and IgG3
preparations. The LIDA of M5, M6, and M9 reacted with
IgG1 only. M11 reacted with both IgG1 and IgG3, and may
thus be a pan-IgG reacting RF (unpublished data). In chronic
gastritis, RF-expressing B cells may theoretically be stimu-
lated by IgG coated on H. pylori or due to existence of cross-
reacting epitopes between H. pylori and IgG-Fc. Upon com-
parison, one H. pylori (strain 26695, GenBank/EMBL/DDBJ
accession no. AE000511) peptide, of the gene product
“virulence-associated protein homologue VacB” (GenBank/
EMBL/DDBJ accession no. AAD08293), was found to share
68% homology with aa 336–354 of the IgG1 Fc at the CH2-
CH3 junction. However, none of M5, M6, M8, M9, M11,
or M14 LIDA, with or without RF activity, reacted with a
synthetic “336-354” peptide, nor did this peptide block the
binding of the RF-LIDAs to IgG. In addition, no binding of
any of these LIDAs to H. pylori–infected HM02 epithelial
cells (strains 26695 and 1061) was observed. In addition, all
LIDAs lacking RF-activity (M8, M14, M23, FL1, FL6 94,
FL8 92, FL13, and B-CLL26) showed no antinuclear anti-
body (ANA) activity on Hep2 cells either (unpublished data).
To explore whether other BCR ligands are present
within the tissue of MALT lymphomas or FLs, we also pro-
duced LIDAs of the IgG class of 3 (non-RF-CDR3-homol-
ogous) MALT lymphomas (M8, M14, and M15) and of 4
FLs (FL1, FL3 93, FL6 94, and FL63; reference 18). These
LIDAs were FITC-labeled and tested immunohistochemi-
cally for reactivity on the corresponding lymphoma tissues.
In none of these experiments however we detected reactiv-
ity with any tissue components (unpublished data).
DISCUSSION
We systematically analyzed the immunoglobulin repertoires
of a comprehensive panel of mature B-NHLs. Unbiased
comparison of IgVH-CDR3–encoded aa sequences of indi-
vidual B-NHLs with all IgVH-CDR3 presently available in
GenBank revealed distinct patterns of the various B-NHL
entities. This provided interesting clues concerning their po-
tential ligands, which was functionally confirmed for the
group of MALT lymphomas.
FLs, DLBCLs, BLs, and myelomas all exhibited a low
degree of overall IgVH-CDR3 sequence homology (Table
V). In none of these 147 B-NHLs, recurrent IgVH-CDR3
motifs were found. The majority of the homologous lym-
phomas expressed CDR3 that resembled those present in
normal B cells. A few, however, shared homology with
B-CLL and MALT lymphomas. One DLBCL displayed ho-
mology with gastric- and salivary gland-MALT lymphomas
as well as with V3-7-RFs (Table V). Thus, in general FL,
DLBCL, BL, and myelomas, all carrying significantly hyper-
mutated IgV genes, seem to recognize unique epitopes, sug-
gesting that they arise randomly out of the pool of B cells se-
lected for nonself-antigens, most likely during the germinal
center reaction. This is in accordance with previous observa-
tions that the germline IgVH gene usage of these B-NHLs is
similar to that of normal peripheral B cells (18, 60). In con-
trast, B-CLL and MCL cases showed a high degree of overall
CDR3 homology (31 and 44%, respectively) (Table V). Fo-
cusing on B-CLL that shared CDR3 homology with at least
two other B-CLL (which held for 37 out of the 308 B-CLL
analyzed), we distinguished eight CDR3-homology groups
(Table VI). These homology groups in part overlap with
B-CLL subgroups as reported by others (49–52). Inter-B-CLL
homology was largely confined to the IgVH-unmutated sub-
set, which shows a strong bias toward V1-69 usage (53): 62
out of 165 (38%) IgVH unmutated B-CLL expressed V1-69,
most often (34/62, 55%) combined with JH6. In addition,
the previously described poly-autoreactivity of a significant
fraction of B-CLL was also clearly reflected in our study:
Eighteen B-CLLs shared CDR3 homology with either of
five B-CLL for which reactivity with auto-Ags such as IgG
(RF), cardiolipin or myoglobulin has been reported (29, 30).
Although the number of available MCL IgVH-CDR3 se-
quences was limited, we observed overall homology for al-
most half of the cases with CDR3 of unmutated IgVH genes
of normal B cells. Still, MCLs are different from B-CLLs
with respect to the IgVH repertoire bias, i.e., with preferen-
tial usage of V3-21 and V4-34 IgVH genes by MCLs (61, 62).
MALT lymphomas were found to express a highly dis-
tinctive IgVH repertoire, confirming and extending earlier
reports by the groups of Miklos et al. (38) and De Re et al.
(63) on salivary gland MALT lymphomas and HCV-associ-
ated B cell lymphomas, respectively. Out of a total of 100
MALT lymphomas that we analyzed, 33 cases shared CDR3
aa homology with other, previously published, CDR3.
Twenty-one of these 33 MALT lymphomas harbored, ac-
cording to the criteria chosen, significant homology to RF-
related CDR3 and, except for one case, could be classified
into either of 3 canonical RF groups; V1-69-RFs, V3-7-
RFs and WOL-RFs (Table V). In addition, 5 salivary gland
MALT lymphomas were included, reported by Bahler et al.
(43, 64) and Miklos et al. (38), which did not completely
fulfill our stringent criteria for V1-69-RFs, but did express
the typical V1-69/JH4 RF gene rearrangement. The RF-
homology group solely involved gastric- and salivary gland-
MALT lymphomas. The in vitro binding studies with the
recombinant LIDA formally proved that MALT lymphomas
with canonical RF IgVH- and IgV -chain rearrangements
and RF-CDR3 homology indeed posses strong RF activity
(Fig. 3). Moreover, MALT lymphomas M9, M21, and M22,
which did not match our criteria for RF homology but of
which M9 and M22 expressed the canonical RF V1-69/JH4
rearrangement, also exhibited strong IgG-binding capacity in
vitro (Fig. 3). Thus, the actual proportion of MALT lym-
phomas with specificity for human IgG is likely to be higher
than calculated on basis of our arbitrary homology criteria.
The degree of RF-CDR3 homology found in the 21
MALT lymphomas is strikingly high, taking into account that
it concerns heavily mutated IgVH genes and that homology in-RHEUMATOID FACTOR PRODUCTION BY MALT LYMPHOMAS | Bende et al. 1238
cluded N-region encoded aa residues (Fig. 2). This suggests a
distinct pathogenesis and indicates that these lymphomas orig-
inate from precursors strongly selected for auto-IgG specific-
ity. The latter notion is well supported by the finding that the
LIDA of the major subclone of M41 (M41-A), with 19 so-
matic mutations, and M41-C, with 20 mutations, exhibited
significant intrinsic IgG-binding activity of the expressed IgVH
chains, whereas this could not be measured of a presumed an-
cestral subclone, M41-D, with 2 mutations (Figs. 1 and 3).
MALT lymphomas typically evolve in a background of
chronic inflammation due to infection or autoimmunity.
Evidence exists that the tumor B cells in gastric MALT lym-
phoma are not H. pylori–specific but largely depend on
CD40 stimulation by H. pylori–specific T helper cells (23). It
has recently been reported, in a murine model, that RF-
expressing B cells can be selectively activated in a T cell in-
dependent manner by IgG-chromatin complexes through the
synergistic engagement of the BCR and toll-like receptor 9
(TLR9; reference 65). TLR9 is expressed in the endoplas-
mic compartment and serves as pathogen sensor that binds
unmethylated CpG DNA motifs which are more common
in bacterial than in mammalian DNA. In the human system,
CpG-DNA was shown to trigger T cell independent prolif-
eration of memory B cells, but not of naive B cells, which
correlated with the levels of TLR9 expression of memory
and naive B cells, respectively (66, 67). Stimulation of TLR9
may thus, parallel to the CD40/CD40L pathway, operate in
lymphoproliferations of MALT. In gastric MALT, RF B
cells may receive synergistic signals of the RF-BCR by IgG–
H. pylori complexes and of TLR9 by H. pylori DNA. Also in
inflamed salivary gland tissue in Sjögren’s syndrome, as well
as in other autoimmune diseases, RF B cells may receive
these signals of the BCR and TLR9 by complexes of IgG
and DNA released during normal or pathological cell death.
This scenario clearly lends support from the fact that virtu-
ally all Sjögren’s syndrome patients produce antinuclear anti-
bodies (ANA), including anti-SS-A and SS-B antibodies.
The most frequent genetic alteration found in MALT
lymphoma is the t(11;18)(q21;q21) encoding an API2-
MALT1 fusion product that constitutively activates the NF-
 B pathway (68). The t(11;18) is present in  40 and  25%
of pulmonary- and gastric-MALT lymphomas respectively
whereas it is virtually absent in MALT lymphomas of the sali-
vary gland ( 2%; references 69–71). We found that  40% of
the salivary gland- and  20% of the gastric-MALT lympho-
mas express RF-like BCRs whereas we did not identify RF-
like BCRs in any of the 19 pulmonary MALT lymphomas. In
addition, none of the MALT lymphomas with a t(11;18) pos-
sessed RF-CDR3 homology (Table VII). Accordingly, the
LIDA of the t(11;18)  lung lymphoma M23 did not bind IgG
in vitro (Fig. 3). This tentative inverse relation between RF-
specificity and the t(11;18) suggests that MALT lymphomas
containing t(11;18) do not depend for their expansion on
BCR-, CD40-, or TLR9-mediated NF- B activation (Table
VII). The fact that t(11;18)  gastric lymphomas are resistant to
H. pylori eradication therapy is in support of this hypothesis
(14, 15). By contrast, the t(11;18)  gastric and salivary gland
MALT lymphomas with RF BCR may need chronic stimu-
lation by IgG in Ag-Ab complexes in gastric- and salivary
gland-MALT lymphomas e.g. as IgG–H. pylori and IgG-ANA
complexes, respectively. Finally, the different Ig repertoire of
t(11;18)  MALT lymphomas, as compared with MALT lym-
phomas devoid of this translocation, indicates that this genetic
alteration as such provides growth advantage and occurs be-
fore the selection process favoring RF-expressing clones.
MATERIALS AND METHODS
Patient material and immunohistochemistry. Frozen or paraffin-
embedded tissue of 23 low-grade and one large cell (M22) MALT lympho-
mas was obtained from the Westeinde Hospital, The Hague; the Free Uni-
versity Medical Center, Amsterdam; The Netherlands Cancer Institute,
Amsterdam and the Academic Medical Center, Amsterdam, The Netherlands.
Tumor cell immunophenotypes were determined by immunohisto-
chemical stainings on acetone-fixed cryostat sections and on formalin-fixed
paraffin embedded sections using the highly sensitive Powervision  detec-
tion system (ImmunoVision Technologies). Monoclonal antibodies used:
IgM,  - and  -light chains (Becton Dickinson), IgG, IgA, CD20 (L26; Da-
koCytomation), CXCR3 (1C6; BD Biosciences), and  4 7 (Act-1).
M22 was a large cell lymphoma consisting of immunoblasts which had
developed in a patient suffering from Sjögren’s syndrome. The original diag-
nosis MALT lymphoma was not made in our hospital and unfortunately we
were not able to recollect material from previous biopsies. This lymphoma
most likely developed from a MALT-associated clone given the expression
of IgA, CXCR3, the mucosa homing receptor  4 7 as well as the obvious
plasmacytoid differentiation with the concurrent lymphoma-related parapro-
teinemia. These are characteristics highly compatible with extranodal mar-
ginal zone lymphomas but extraordinary for diffuse large B cell lymphomas.
This study was conducted in accordance with the ethical standards in our
institutional medical ethical committee on human experimentation, as well as
in agreement with the Helsinki Declaration of 1975, as revised in 1983.
DNA and RNA isolation; cDNA synthesis; and IgVH, IgV , and
t(11;18) RT-PCR. DNA was isolated from paraffin sections by over night
proteinase K digestion. RNA was isolated from frozen sections using the
Table VII. Relation between the presence of t(11;18) and 
RF-CDR3 homology and/or RF activity of MALT lymphoma 
immunoglobulins
t(11;18)
and RF homology/
activity of
24 MALT lymphomas
Frequencies of t(11;18)
and RF homology among
MALT lymphoma cohorts
t(11;18)a
n    n t(11;18)b n RF-CDR3c
(%) (%)
Salivary gland 6 0 (0) 6 (4) 114 2 (2) 32 13 (41)
Gastric 10 5 (0) 5 (2) 209 50 (24) 45 8 (18)
Pulmonary 4 3 (0) 1 (0) 113 47 (42) 19 0 (0)
Other MALT 4 0 (0) 4 (1) ND NA 4 0 (0)
aNumbers in parentheses indicate quantity of cases with RF-CDR3 homology and/or 
in vitro RF activity.
bThe data on t(11;18) and MALT lymphoma localization refer to combined data 
described previously (69–71).
cData adapted from Table V.
NA, not applicable.JEM VOL. 201, April 18, 2005 1239
ARTICLE
TRIzol reagent (Invitrogen) and cDNA was synthesized with Pd(N)6 ran-
dom primers. The IgVH and IgV  genes were amplified using IgVH and IgV 
family-specific leader primers combined with the appropriate reverse primer
being either JH, C , C , C , J , or C . To determine the clonally ex-
pressed IgVH gene of the tumor B cells, the CDR3 region was also amplified,
directly on cDNA and in nested PCRs on the IgVH family-specific PCR
products, using a forward primer specific for the framework region 3 (FR3)
in combination with one of the different nested downstream primers specific
for JH, C , C , C  or C . The PCR programs and primers sequences were
described previously (18, 58). Translocation t(11;18) was determined using
the primers and the PCR program as described by Liu et al. (15).
Cloning and sequencing. IgV RT-PCR products of MALT lymphomas
were either directly sequenced or cloned into pTOPO-TA-vectors and
transformed into TOP10 bacteria (Invitrogen), to generate molecular IgV
clones. Sequencing on both strands was performed by an ABI sequencer
(Applied Biosystems) using the big dye-terminator cycle-sequencing kit.
To identify the IgV germline gene used and the somatic mutations therein,
the consensus sequence of each MALT lymphoma was compared with
published germline sequences, using the Vbase database (72) and DNAplot
on internet (http://www.mrc-cpe.cam.ac.uk). The IgV sequences of the
MALT lymphomas were deposited on GenBank/EMBL/DDBJ (accession
nos. AY281324-AY281343, AY466502, AY466503, AY561708 and
AY927657-AY927668). The degree of intraclonal variation (ICV) of IgVH
genes and IgV  genes was calculated as the mean number of nucleotide dif-
ferences of each molecular clone as compared with the consensus IgVH or
IgV  sequences (18). ICV was considered significant if exceeding 0.4 muta-
tions/clone.
Production of IgM antibodies derived of B-NHL. Recombinant
IgM  antibodies of the lymphomas (lymphoma-idiotype-derived Ab
[LIDA]) of patients M5, M6, M8, M9, M11, M14, M21, M22, M23, M41,
FL1, FL6 94, FL8 92, and B-CLL26 were produced using the pIgH( )
and pIgL( ) expression vectors as described previously (59). In brief, the
IgVH and IgV  sequences of each of these lymphomas, including one EBV
B cell clone (8D8), which produces a human monoclonal antibody specific
for the erythrocyte Rhesus(D) blood group antigen (57), were each cloned
into the pIgH( ) and pIgL( ) vectors respectively. For production of re-
combinant antibody, 10  g pIgH( ) and 10  g pIgL( ) were linearized
with PvuI and cotransfected into SP2/0 myeloma cells by electroporation.
Subsequently, the transfected cells were selected in geneticin-containing
medium. The IgVH of M41-A, C, and D were expressed with the IgV  of
M22. An Ig-secreting heterohybridoma of an IgM  expressing FL FL13
(18), was produced by electrofusion with F3B6 (73) as described previously
(74). LOS3 and VT-7G3 are an IgM  and an IgA  anti-Rhesus(D)-secret-
ing EBV B cell clone, respectively (57). Supernatants were screened for
IgM  or IgM , using ELISAs as described previously (57). The pIgH( )
and pIgL( ) expression vectors were provided by J. van Es and T. Logten-
berg (Utrecht Medical Center, Utrecht, The Netherlands).
LIDA reactivity in rheumatoid factor ELISA and on H. pylori–
infected HM02 cells. LIDA reactivity with hIgG was determined using
the IgM Rheumatoid Factor ELISA kit (Sanquin) according to the manu-
facturer’s instructions. The plates were developed using TMB as substrate, as
described previously (57). For IgA RF activity, a HRP-labeled rabbit anti-
IgA Ab (DakoCytomation) was used. The “336-354” IgG1 Fc peptide was
coated at 4  g/ml, incubated with LIDA, followed by mAb anti-IgM-HRP
(MH15/1-HRP; Sanquin), and developed as described previously (57). For
blocking RF activity, LIDAs were tested in RF-ELISA in the presence of a
50–500 molar excess of the “336-354” IgG1 Fc peptide. To detect LIDA
reactivity with H. pylori,  80% confluent cultures of HM02 cells were in-
cubated with 2*106 CFU H. pylori (strains 1061 and 26695) and cultured for
1 wk. The cells were then fixed with methanol-aceton (1:1), immunocy-
tochemically stained with LIDA, HRP labeled rabbit anti-IgM Ab (Dako-
Cytomation) and developed with AEC as substrate.
Online supplemental material. Table S1 summarizes the IgVH-CDR3
amino acid sequence homology of MALT lymphomas M5, M6, M11, and
M41 with other normal and malignant B cells as well as with RF-producing
B cells. Table S2 gives an overview of the IgV -CDR3 amino acid se-
quences of the MALT lymphomas of Table III. The supplemental legend to
Table V summarizes all lymphomas used in the IgVH-CDR3 homology anal-
ysis. The supplemental legend to Table VI depicts the B-CLL cases belonging
to the eight IgVH-CDR3 homology groups and their resemblance to homol-
ogy groups as described previously (49–52). Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20050068/DC1.
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